Emergent BioSolutions Inc. EBS
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -44.90%
- 1 year
- -46.96%
- Open
- 7.11
- Prev close
- 7.22
- Mkt cap
- 349.17M
- Vol
- 754.44K
- Avg vol
- 1.23M
- EPS
- -3.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.77
- High
- 7.30
- Forward P/E
- 2.73
- Beta
- 1.57
- Short ratio
- 4.54
- Inst. own
- 60.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.27
- 200-d avg
- 7.13
- 1y target
- 12.00
5Y chart
Events in this range
- May 9, 2023Earnings: -3.17; estimate -1.67; surprise -89.82%
- Aug 8, 2023Earnings: -1.06; estimate -0.98; surprise -8.16%
- Mar 6, 2024Earnings: -0.77; estimate -0.33; surprise -133.33%
- May 1, 2024Earnings: 0.59; estimate 0; surprise —%
- Jul 3, 2024Rating: Benchmark · Buy → Buy
- Aug 6, 2024Earnings: -2.32; estimate -0.97; surprise -139.18%
- Aug 9, 2024Rating: Benchmark · Buy → Buy
- Aug 16, 2024Rating: Benchmark · Buy → Buy
- Aug 22, 2024Rating: Rodman & Renshaw · — → Buy
- Sep 13, 2024Rating: Rodman & Renshaw · Buy → Buy
- Nov 6, 2024Earnings: 1.37; estimate 0.49; surprise 179.59%
- Nov 7, 2024Rating: Benchmark · Buy → Buy
Signals (84)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| RSI: Oversold | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| SMA: Bullish | May 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Sep 30, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 2, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| RSI: Overbought | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| RSI: Oversold | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 6, 2023 | 2 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| RSI: Oversold | Sep 11, 2023 | 3 years ago |
| RSI: Oversold | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 19, 2023 | 3 years ago |
| SMA: Bearish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 2, 2023 | 3 years ago |
| RSI: Oversold | Nov 14, 2022 | 3 years ago |
| MACD: Sell Signal | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Jan 24, 2022 | 4 years ago |
Key statistics
- Market cap
- 441.60M
- Enterprise value
- 964.99M
- Trailing P/E
- 0.00
- Forward P/E
- 2.73
- PEG ratio
- 0.00
- Price / sales
- 0.39
- Price / book
- 0.87
- EPS (TTM)
- -3.91
- Beta
- 1.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -18.55%
- Revenue (TTM)
- 1.13B
- Revenue growth
- 8.60%
- Free cash flow
- 89.59M
- Total cash
- 149.90M
- Total debt
- 676.00M
- Return on equity
- -34.64%
- Shares outstanding
- 54.18M
- Short % of float
- 15.53%
- 50-day average
- 9.27
- 200-day average
- 7.13
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | 0.49 | 1.37 | +0.88 | +179.59% |
| Aug 6, 2024 | Jun 1, 2024 | -0.97 | -2.32 | -1.35 | -139.18% |
| May 1, 2024 | Mar 1, 2024 | 0.00 | 0.59 | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.33 | -0.77 | -0.44 | -133.33% |
| Aug 8, 2023 | Jun 1, 2023 | -0.98 | -1.06 | -0.08 | -8.16% |
| May 9, 2023 | Mar 1, 2023 | -1.67 | -3.17 | -1.50 | -89.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Benchmark | main | Buy | Buy |
| Sep 13, 2024 | Rodman & Renshaw | reit | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 16, 2024 | Benchmark | reit | Buy | Buy |
| Aug 9, 2024 | Benchmark | reit | Buy | Buy |
| Jul 3, 2024 | Benchmark | reit | Buy | Buy |
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- emergentbiosolutions.com
News
- Novavax Shorts on Edge as Russia Plague Fears Spread
- HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target
- Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS
- Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029
- World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
- HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
- Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Your note
Sign in to keep a note on EBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAYAL SUJATA TYAGI | Director | Stock Award(Grant) | May 22, 2024 | 63,129 |
| DEGOLYER DONALD W | Director | Sale | Nov 11, 2024 | 111,100 |
| FOWLER NEAL FRANKLIN | Director | Stock Award(Grant) | May 22, 2024 | 136,100 |
| FOX JENNIFER LYNNE | General Counsel | Stock Award(Grant) | Jul 10, 2024 | 186,382 |
| HARTZEL WILLIAM | Officer | Stock Award(Grant) | Jul 10, 2024 | 48,107 |
| KATKIN KEITH A | Director | Stock Award(Grant) | May 22, 2024 | 59,872 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 6.27% | 3,397,626 | 27.69M | Sep 29, 2024 |
| Marshall Wace LLP | 4.60% | 2,494,584 | 20.33M | Sep 29, 2024 |
| Charles Schwab Investment Management, Inc. | 4.11% | 2,224,727 | 18.13M | Sep 29, 2024 |
| Blackrock Inc. | 3.68% | 1,993,680 | 16.25M | Sep 29, 2024 |
| State Street Corporation | 3.53% | 1,911,327 | 15.58M | Sep 29, 2024 |
| American Century Companies Inc | 3.20% | 1,733,045 | 14.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF | 4.36% | 2,359,820 | 19.23M | Aug 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.06% | 1,655,564 | 13.49M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.02% | 1,636,319 | 13.34M | Sep 29, 2024 |
| Avantis U.S. Small Cap Value ETF | 2.63% | 1,425,865 | 11.62M | Sep 29, 2024 |
| Invesco ETF Tr-Invesco FTSE RAFI US 1500 Small-Mid ETF | 1.66% | 900,912 | 7.34M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.51% | 815,636 | 6.65M | Sep 29, 2024 |